Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram

European Urology

Volumn 56, Issue 4, 2009, Pages 659-668

  Chun, Felix K ^a   de la Taille, Alexandre ^b   van Poppel, Hendrik ^c   Marberger, Michael ^d   Stenzl, Arnulf ^e   Mulders, Peter F A ^f   Huland, Hartwig ^a   Abbou, Clement Claude ^b   Stillebroer, Alexander B ^f   van Gils, Martijn P M Q ^f   Schalken, Jack A ^f   Fradet, Yves ^g   Marks, Leonard S ^h   Ellis, William ⁱ   Partin, Alan W ^j   Haese, Alexander ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITÉ LAVAL   (Canada)

^h Urological Sci Research Foundation   (United States)

ⁱ UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Biomarker; Nomogram; Prostate biopsy; Prostate cancer; Prostate cancer gene 3; Risk assessment

Indexed keywords

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; VALIDATION PROCESS;

EID: 69249235710     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.03.029     Document Type: Article

References (24)

1. Groskopf J., Aubin S.M., Deras I.L., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52 (2006) 1089-1095
2. PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44 (2003) 8-16 discussion 15-6
3. Van Gils M.P., Cornel E.B., Hessels D., et al. Molecular PCA3 diagnostics on prostatic fluid. Prostate 67 (2007) 881-887
4. Marks L.S., Fradet Y., Deras I.L., et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69 (2007) 532-535
5. Deras I.L., Aubin S.M., Blase A., et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179 (2008) 1587-1592
6. Kattan M.W. Evaluating a new marker's predictive contribution. Clin Cancer Res 10 (2004) 822-824
7. Kattan M.W. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 95 (2003) 634-635
8. Eskew L.A., Bare R.L., and McCullough D.L. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 157 (1997) 199-202 discussion 202-3
9. Gerstenbluth R.E., Seftel A.D., Hampel N., et al. The accuracy of the increased prostate specific antigen level (greater than or equal to 20 ng/ml) in predicting prostate cancer: is biopsy always required?. J Urol 168 (2002) 1990-1993
10. Mazumdar M., and Glassman J.R. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med 19 (2000) 113-132
11. Chun F.K., Haese A., de la Taille A., et al. Performance analysis of different PCA3 cut-offs. J Urol 179 (2008) 705
12. Haese A., de la Taille A., van Poppel H., et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54 (2008) 1081-1088
13. Ankerst D.P., Groskopf J., Day J.R., et al. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol 180 (2008) 1303-1308 discussion 1308
14. Chun F.K.-H., Briganti A., Graefen M., et al. Development and external validation of an extended 10-core biopsy nomogram. Eur Urol 52 (2007) 436-445
15. Chun F.K., Briganti A., Graefen M., et al. Development and external validation of an extended repeat biopsy nomogram. J Urol 177 (2007) 510-515
16. Nam R.K., Toi A., Klotz L.H., et al. Assessing individual risk for prostate cancer. J Clin Oncol 25 (2007) 3582-3588
17. Canto E.I., Singh H., Shariat S.F., et al. Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. J Urol 172 (2004) 900-904
18. Shariat S.F., Karam J.A., Walz J., et al. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res 14 (2008) 3785-3791
19. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
20. Klotz L. Active surveillance for prostate cancer: for whom?. J Clin Oncol 23 (2005) 8165-8169
21. Chun F.K., Haese A., Ahyai S.A., et al. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer 113 (2008) 701-709
22. Nakanishi H., Groskopf J., Fritsche H.A., et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 179 (2008) 1804-1809 discussion 1809-10
23. Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529-534
24. Briganti A., Chun F.K., Suardi N., et al. Prostate volume and adverse prostate cancer features: fact not artifact. Eur J Cancer 43 (2007) 2669-2677